Physical performance tests have excellent reliability in frail and non-frail patients with prostate cancer

Feyzioğlu, Özlem; Dinçer, Selvi; Özdemir, Ayşem Ecem; Öztürk, Özgül

doi:10.1080/09638288.2024.2340703

Disability and Rehabilitation

2024

DOI: 10.1080/09638288.2024.2340703

|View full text |Cite

Physical performance tests have excellent reliability in frail and non-frail patients with prostate cancer

Özlem Feyzioğlu,

Selvi Dinçer,

Ayşem Ecem Özdemir

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study

Beer,

George,

Shore

et al. 2024

The Oncologist

View full text Add to dashboard Cite

Background Androgen receptor inhibitors (ARIs) are approved for the treatment of advanced prostate cancer; however, some patients may experience symptoms and side effects that hinder their physical functioning. The Timed Up and Go (TUG) and Short Physical Performance Battery (SPPB) tests are used to assess physical functioning in older adults and are recommended assessments for patients with prostate cancer, despite lacking validation in this setting. Methods DaroAct (NCT04157088) was an open-label, multicenter, phase 2b study designed to evaluate the effects of the ARI darolutamide (lead-in phase) and darolutamide vs enzalutamide (randomized phase) on physical functioning in men with castration-resistant prostate cancer (CRPC). Only the lead-in phase, in which participants received darolutamide 600 mg twice daily, was completed. The TUG and SPPB tests were used to assess physical functioning. Results The lead-in phase enrolled 30 participants. During 24 weeks of treatment, 8 (32.0%) of 25 evaluable participants exhibited clinically meaningful worsening in TUG from baseline (primary endpoint). At the week 24 visit, 5 (21.7%) of 23 participants had worsening in TUG time, and 8 (33.3%) of 24 participants had worsening in SPPB score. Because only 48% of participants had the same outcome on the TUG and SPPB tests, the study was terminated without initiating the randomized comparison. Conclusion Most participants showed no clinically meaningful worsening in physical functioning after 24 weeks of darolutamide treatment, but poor agreement between tests was observed. Tools to accurately and consistently measure the impact of ARIs on physical functioning in patients with CRPC are needed.

show abstract

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study

Beer,

George,

Shore

et al. 2024

The Oncologist

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Physical performance tests have excellent reliability in frail and non-frail patients with prostate cancer

Cited by 1 publication

References 55 publications

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study

Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study

Contact Info

Product

Resources

About